The IL-23/Th17 axis: therapeutic targets for autoimmune inflammation [Current Opinion in Immunology 2006, 18:670-675] (DOI:10.1016/j.coi.2006.09.008);The IL-23/Th17 axis: therapeutic targets for autoimmune inflammation

Current Opinion in Immunology

Volumn 18, Issue 6, 2006, Pages 670-675

  Kikly, Kristine ^a   Liu, Ling ^a   Na, Songqing ^a   Sedgwick, Jonathon D ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; CHEMOKINE; CYTOKINE; CYTOKINE ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR ANTIBODY; INTERLEUKIN 17; INTERLEUKIN 17 ANTIBODY; INTERLEUKIN 23; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; MONOCLONAL ANTIBODY; STEROID; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; CYTOKINE PRODUCTION; DISEASE COURSE; DRUG EFFECT; ENTERITIS; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATORY DISEASE; MULTIPLE SCLEROSIS; PATHOGENESIS; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; TH1 CELL; TREATMENT OUTCOME;

EID: 33750282677     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2006.11.016     Document Type: Erratum

References (55)

1. McKenzie B.S., Kastelein R., and Cua D.J. Understanding the IL-23-IL-17 immune pathway. Trends Immunol 27 (2006) 17-23
2. 17 cells using an infectious disease model. It also shows that TGF-β1 induces the IL-23R in T cells.
3. Hunter C.A. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol 5 (2005) 521-531. This is a review of structural and functional data and the relationship to other closely related cytokines. It provides an extensive review of historical data from animal models of autoimmunity and infectious disease concerning the IL-12 axis and the relationship to new data regarding the IL-23/Th17 axis.
4. 17 as a novel effector T-cell population.
5. Murphy C.A., Langrish C.L., Chen Y., Blumenschein W., McClanahan T., Kastelein R.A., Sedgwick J.D., and Cua D.J. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 198 (2003) 1951-1957
6. Park H., Li Z., Yang X.O., Chang S.H., Nurieva R., Wang Y.H., Wang Y., Hood L., Zhu Z., Tian Q., et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 6 (2005) 1133-1141
7. + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6 (2005) 1123-1132
8. Hoeve M.A., Savage N.D., de Boer T., Langenberg D.M., de Waal Malefyt R., Ottenhoff T.H., and Verreck F.A. Divergent effects of IL-12 and IL-23 on the production of IL-17 by human T cells. Eur J Immunol 36 (2006) 661-670
9. 17 cells.
10. 17 cells infiltrating the central nervous system.
11. 17 differentiation.
12. Kolls J.K., and Linden A. Interleukin-17 family members and inflammation. Immunity 21 (2004) 467-476
13. 't Hart B.A., Brok H.P., Remarque E., Benson J., Treacy G., Amor S., Hintzen R.Q., Laman J.D., Bauer J., and Blezer E.L. Suppression of ongoing disease in a nonhuman primate model of multiple sclerosis by a human-anti-human IL-12p40 antibody. J Immunol 175 (2005) 4761-4768
14. Cua D.J., Sherlock J., Chen Y., Murphy C.A., Joyce B., Seymour B., Lucian L., To W., Kwan S., Churakova T., et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421 (2003) 744-748
15. Yen D., Cheung J., Scheerens H., Poulet F., McClanahan T., McKenzie B.S., Kleinschek M.A., Owyang A.M., Mattson J., Blumenschein W., et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 116 (2006) 1310-1316
16. Chen Y., Langrish C.L., McKenzie B.S., Joyce-Shaikh B., Stumhofer J.S., McClanahan T., Blumenschein W., Churakova T., Low J., Presta L., et al. Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J Clin Invest 116 (2006) 1317-1326. This is the first article to demonstrate that neutralization of IL-23 in vivo, using an anti-p19 antibody rather than gene targeting, shows therapeutic efficacy in an EAE model by measuring a reduction in both the clinical score and pro-inflammatory cytokine and chemokine expression in the spinal cord.
17. Samoilova E.B., Horton J.L., Hilliard B., Liu T.S., and Chen Y. IL-6-deficient mice are resistant to experimental autoimmune encephalomyelitis: roles of IL-6 in the activation and differentiation of autoreactive T cells. J Immunol 161 (1998) 6480-6486
18. Eugster H.P., Frei K., Kopf M., Lassmann H., and Fontana A. IL-6-deficient mice resist myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. Eur J Immunol 28 (1998) 2178-2187
19. Sasai M., Saeki Y., Ohshima S., Nishioka K., Mima T., Tanaka T., Katada Y., Yoshizaki K., Suemura M., and Kishimoto T. Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice. Arthritis Rheum 42 (1999) 1635-1643
20. Campbell I.K., Rich M.J., Bischof R.J., Dunn A.R., Grail D., and Hamilton J.A. Protection from collagen-induced arthritis in granulocyte-macrophage colony-stimulating factor-deficient mice. J Immunol 161 (1998) 3639-3644
21. McQualter J.L., Darwiche R., Ewing C., Onuki M., Kay T.W., Hamilton J.A., Reid H.H., and Bernard C.C. Granulocyte macrophage colony-stimulating factor: a new putative therapeutic target in multiple sclerosis. J Exp Med 194 (2001) 873-882
22. Nakae S., Nambu A., Sudo K., and Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 171 (2003) 6173-6177
23. Takagi N., Mihara M., Moriya Y., Nishimoto N., Yoshizaki K., Kishimoto T., Takeda Y., and Ohsugi Y. Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis Rheum 41 (1998) 2117-2121
24. Lubberts E., Koenders M.I., Oppers-Walgreen B., van den Bersselaar L., Coenen-de Roo C.J., Joosten L.A., and van den Berg W.B. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 50 (2004) 650-659
25. Ware C.F. Network communications: lymphotoxins, LIGHT, and TNF. Annu Rev Immunol 23 (2005) 787-819
26. Nishimoto N: Interleukin-6 in rheumatoid arthritis. Curr Opin Rheumatol 18:277-281.
27. Lee E., Trepicchio W.L., Oestreicher J.L., Pittman D., Wang F., Chamian F., Dhodapkar M., and Krueger J.G. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 199 (2004) 125-130
28. Piskin G., Sylva-Steenland R.M., Bos J.D., and Teunissen M.B. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol 176 (2006) 1908-1915
29. Piskin G., Tursen U., Sylva-Steenland R.M., Bos J.D., and Teunissen M.B. Clinical improvement in chronic plaque-type psoriasis lesions after narrow-band UVB therapy is accompanied by a decrease in the expression of IFN-γ inducers-IL-12, IL-18 and IL-23. Exp Dermatol 13 (2004) 764-772
30. Gottlieb A.B., Chamian F., Masud S., Cardinale I., Abello M.V., Lowes M.A., Chen F., Magliocco M., and Krueger J.G. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol 175 (2005) 2721-2729
31. Chamian F., Lowes M.A., Lin S.L., Lee E., Kikuchi T., Gilleaudeau P., Sullivan-Whalen M., Cardinale I., Khatcherian A., Novitskaya I., et al. Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc Natl Acad Sci USA 102 (2005) 2075-2080
32. Kauffman C.L., Aria N., Toichi E., McCormick T.S., Cooper K.D., Gottlieb A.B., Everitt D.E., Frederick B., Zhu Y., Graham M.A., et al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol 123 (2004) 1037-1044
33. Ziolkowska M., Koc A., Luszczykiewicz G., Ksiezopolska-Pietrzak K., Klimczak E., Chwalinska-Sadowska H., and Maslinski W. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J Immunol 164 (2000) 2832-2838
34. Cho M.L., Yoon C.H., Hwang S.Y., Park M.K., Min S.Y., Lee S.H., Park S.H., and Kim H.Y. Effector function of type II collagen-stimulated T cells from rheumatoid arthritis patients: cross-talk between T cells and synovial fibroblasts. Arthritis Rheum 50 (2004) 776-784
35. Chabaud M., Durand J.M., Buchs N., Fossiez F., Page G., Frappart L., and Miossec P. Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 42 (1999) 963-970
36. Joosten L.A., Radstake T.R., Lubberts E., van den Bersselaar L.A., van Riel P.L., van Lent P.L., Barrera P., and van den Berg W.B. Association of interleukin-18 expression with enhanced levels of both interleukin-1beta and tumor necrosis factor alpha in knee synovial tissue of patients with rheumatoid arthritis. Arthritis Rheum 48 (2003) 339-347
37. Vaknin-Dembinsky A., Balashov K., and Weiner H.L. IL-23 is increased in dendritic cells in multiple sclerosis and down-regulation of IL-23 by antisense oligos increases dendritic cell IL-10 production. J Immunol 176 (2006) 7768-7774
38. Matusevicius D., Kivisakk P., He B., Kostulas N., Ozenci V., Fredrikson S., and Link H. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 5 (1999) 101-104
39. Lock C., Hermans G., Pedotti R., Brendolan A., Schadt E., Garren H., Langer-Gould A., Strober S., Cannella B., Allard J., et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 8 (2002) 500-508
40. Schmidt C., Giese T., Ludwig B., Mueller-Molaian I., Marth T., Zeuzem S., Meuer S.C., and Stallmach A. Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn's disease but not in ulcerative colitis. Inflamm Bowel Dis 11 (2005) 16-23
41. Stallmach A., Giese T., Schmidt C., Ludwig B., Mueller-Molaian I., and Meuer S.C. Cytokine/chemokine transcript profiles reflect mucosal inflammation in Crohn's disease. Int J Colorectal Dis 19 (2004) 308-315
42. Fujino S., Andoh A., Bamba S., Ogawa A., Hata K., Araki Y., Bamba T., and Fujiyama Y. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 52 (2003) 65-70
43. Mannon P.J., Fuss I.J., Mayer L., Elson C.O., Sandborn W.J., Present D., Dolin B., Goodman N., Groden C., Hornung R.L., et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 351 (2004) 2069-2079
44. + TH1-like responses. J Clin Invest 98 (1996) 1010-1020
45. Dumont F.J. Fontolizumab: Protein Design Labs. Curr Opin Investig Drugs 6 (2005) 537-544
46. Skurkovich S., Boiko A., Beliaeva I., Buglak A., Alekseeva T., Smirnova N., Kulakova O., Tchechonin V., Gurova O., Deomina T., et al. Randomized study of antibodies to IFN-γ and TNF-α in secondary progressive multiple sclerosis. Mult Scler 7 (2001) 277-284
47. Sigidin Y.A., Loukina G.V., Skurkovich B., and Skurkovich S. Randomized, double-blind trial of anti-interferon-gamma antibodies in rheumatoid arthritis. Scand J Rheumatol 30 (2001) 203-207
48. Langowski J.L., Zhang X., Wu L., Mattson J.D., Chen T., Smith K., Basham B., McClanahan T., Kastelein R., and Oft M. IL-23 promotes tumor incidence and growth. Nature 442 (2006) 461-465
49. Maeda A., Schneider S.W., Kojima M., Beissert S., Schwarz T., and Schwarz A. Enhanced photocarcinogenesis in interleukin-12-deficient mice. Cancer Res 66 (2006) 2962-2969
50. Proudfoot A.E. Chemokine receptors: multifaceted therapeutic targets. Nat Rev Immunol 2 (2002) 106-115
51. Godiska R., Chantry D., Dietsch G.N., and Gray P.W. Chemokine expression in murine experimental allergic encephalomyelitis. J Neuroimmunol 58 (1995) 167-176
52. Ruth J.H., Shahrara S., Park C.C., Morel J.C., Kumar P., Qin S., and Koch A.E. Role of macrophage inflammatory protein-3α and its ligand CCR6 in rheumatoid arthritis. Lab Invest 83 (2003) 579-588
53. Columba-Cabezas S., Serafini B., Ambrosini E., Sanchez M., Penna G., Adorini L., and Aloisi F. Induction of macrophage-derived chemokine/CCL22 expression in experimental autoimmune encephalomyelitis and cultured microglia: implications for disease regulation. J Neuroimmunol 130 (2002) 10-21
54. Cho M.L., Kang J.W., Moon Y.M., Nam H.J., Jhun J.Y., Heo S.B., Jin H.T., Min S.Y., Ju J.H., Park K.S., et al. STAT3 and NF-κB signal pathway is required for IL-23-mediated IL-17 production in spontaneous arthritis animal model IL-1 receptor antagonist-deficient mice. J Immunol 176 (2006) 5652
55. Sutton C., Brereton C., Keogh B., Mills K.H., and Lavelle E.C. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J Exp Med 203 (2006) 1685